Corporativo Fragua, S.A. (CGSBF) Fair Value & Analysis
Healthcare · US · Market cap $2.8B
Corporativo Fragua, S.A.
CGSBF · US
Fair value as of: Jul 15, 2026
From 25 valuation models · updated 26 days ago
Fair value updated Jul 15, 2026, revised from $40.13 to $40.34 (+0.5%) since Jun 24, 2026.
A solid business, screening 36% undervalued on our models.
What matters now
- The model range is unusually wide ($22.47 to $67.23). The outcome hinges heavily on assumptions, so read the point estimate with caution.
- Solid quality (55/100) at a price below fair value, the discount is the argument here, not the business quality.
Price vs Fair Value (4 months)
White line = price, green steps = our fair value per fiscal year. As of Jul 15, 2026.
How to read this chart
4‑month range $29.66 – $29.66 · fair‑value band $22.47 – $67.23 · the $29.66 price screens below the $40.34 fair value. As of Jul 15, 2026.
Analysis
Corporativo Fragua, S.A. (CGSBF) currently trades at $29.66, while our model-based Fair Value estimate is $40.34, implying the stock looks roughly 36.0% undervalued today. The Quality Score stands at 55/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium), always confirm before acting.
Over the trailing twelve months, Corporativo Fragua, S.A. generated revenue of $134B at a net margin of 3.4%. Revenue grew 7.1% year over year. It earns a return on equity of 16.5%. The stock trades on a trailing P/E of 11.0. Fundamentals as of Jul 15, 2026
Our scenario range runs from $22.47 (bear case) to $67.23 (bull case); at $29.66, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades near its 52-week high, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -15% fair-value upside, at 36%, CGSBF screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 25 models by family
Widest divergence: Growth Earnings ($902.52) versus Growth DCF ($74.29). Highest evidence: Growth DCF (80).
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 15, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 54 · Market factors (momentum, volatility) 60
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Corporativo Fragua, S.A.B. de C.V., together with its subsidiaries, operates pharmacy stores in Mexico. The company purchases and sells medicine products, perfumes, photography equipment, household goods, food, miscellaneous items, and others.
Full company description
Corporativo Fragua, S.A.B. de C.V., together with its subsidiaries, operates pharmacy stores in Mexico. The company purchases and sells medicine products, perfumes, photography equipment, household goods, food, miscellaneous items, and others. It is also involved in the provision of maintenance and surveillance services, and medical services; operation service of distribution centers; management, logistics, and personnel services; maintenance and repair of furniture; transport and distribution of goods; purchase, sale, and rental of buildings; and manufacture and packaging of non-alcoholic beverages. The company was founded in 1942 and is based in Guadalajara, Mexico.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2024 · reported fiscal years
Corporativo Fragua, S.A. reported revenue of $120B in FY2024 versus $84.8B in FY2021, a compound +12.3%/yr. Reported net income was $4.9B in FY2024, compounding +23.2%/yr from FY2021.
Watch CGSBF: get an alert when its fair value changes →
Peer Group
Pharmaceutical Retailers · 61 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Pharmaceutical Retailers median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Pharmaceutical Retailers stocks, each showing price versus our Fair Value estimate (as of Jul 15, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| JD Health International Inc 6618 | HK$39.20 | HK$33.28 | -15% |
| Raia Drogasil S.A RADL3 | R$18.20 | R$15.58 | -14% |
| Yifeng Pharmacy Chain Co 603939 | ¥20.24 | ¥29.07 | +44% |
| DaShenLin Pharmaceutical Group 603233 | ¥17.81 | ¥23.86 | +34% |
| LBX Pharmacy Chain Joint Stock Company 603883 | ¥11.51 | ¥10.57 | -8% |
| MedPlus Health Services Limited MEDPLUS | ₹690.20 | ₹379.25 | -45% |
| Yixintang Pharmaceutical Group 002727 | ¥11.46 | ¥9.45 | -18% |
| Anhui Huaren Health Pharmaceutical Co 301408 | ¥14.40 | ¥10.05 | -30% |
| Apotea AB APOTEA | kr 74.75 | kr 43.95 | -41% |
| ShuYu Civilian Pharmacy Corp 301017 | ¥13.34 | ¥5.91 | -56% |
Compare Corporativo Fragua, S.A. with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Corporativo Fragua, S.A. (CGSBF) overvalued or undervalued?
What is the fair value of CGSBF?
What is the quality score of CGSBF?
What is the revenue of Corporativo Fragua, S.A. (CGSBF)?
What is the net profit margin of CGSBF?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Corporativo Fragua, S.A. and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.